All publications of “Carmelia Maria Noia Barreto”

2 results

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar Jr. ORCID logo , Pui San Tan ORCID logo , Sarah Simko ORCID logo , Carmelia Maria Noia Barreto ORCID logo , Bárbara de Souza Gutierres ORCID logo , Auro del Giglio ORCID logo , [...]

DOI: 10.31744/einstein_journal/2019GS4414

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted […]

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Pedro Nazareth Aguiar Jr., Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, Hakaru Tadokoro, Gilberto de Lima Lopes Jr

DOI: 10.1590/S1679-45082017GS4017

ABSTRACT Objective To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. Methods An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer. The cost-effectiveness in metastatic patients with a high-volume disease was assessed separately. The model used data from randomized clinical trials and drug acquisition costs in Brazil. In addition, […]